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Allergy is the most widespread immunologic
disorder in humans. It affects one in four
individuals (HayGlass 1995). Today, 50 mil-
lion Americans suffer from this disease and
15 million of them have asthma (Wasserman
1999). Allergy is defined as a T helper 2
(Th2)-driven hypersensitivity to innocuous
antigens (allergens) of complex genetic and
environmental origin and is acknowledged as
a major risk factor for asthma (Holt et al.
1999). Allergens are derived from different
sources. Both indoor allergens (house dust
mite, cockroach, fungi, mold, animal-derived
substances) and selected outdoor allergens
(tree, weed, and grass pollens, fungal spores)
have been implicated in causing asthma
(Burge and Rogers 2000; Moore et al. 2001;
Platts-Mills et al. 2000).
Despite much progress in understanding
allergies—the dysfunction of the immune sys-
tem (Campbell and Weiss 1999)—the molec-
ular and genetic predisposition to allergy has
not been identified. Identification of these
factors is critical in managing atopic individu-
als (Cookson 1999). Recently, genome-wide
searches and candidate gene approaches have
been used to examine the possible involve-
ment of several genes in the development of
atopy and asthma. The regions of potential
linkage to one or more asthma phenotypes
were identiﬁed on chromosomes 5q, 6p, 11q,
12q, 13q, and 14q (Blumenthal 2000;
Cookson 1999; Ono 2000).
Human leukocyte antigen (HLA) mole-
cules are encoded by highly polymorphic gene
families located on chromosome 6p. These
molecules play a critical role in the initiation
of immune responses to allergens because
they bind allergen-derived peptides and pre-
sent them to T lymphocytes, resulting in T
cell activation and proliferation (Figure 1).
CD4+ Th2 cells are at the cellular epicenter of
allergic disease. They produce an array of
cytokines that directly or indirectly cause an
acute and chronic allergic reaction in the air-
ways (Figure 1). However, CD4+ T-cell
response to particular allergen/antigen criti-
cally depends on the genotype of HLA II, on
the difference in their physicochemical char-
acteristics of the molecular structure, and on
binding and presentation of distinct peptides
to CD4+ T cells (Klein and Sato 2000; Little
and Parham 1999).
The association of HLA haplotypes and
short ragweed (SRW) allergy was the first
human immune response (Ir) gene to be rec-
ognized (Levine et al. 1972), and HLA-DR2
and HLA-DQ6 restriction of immunoglobu-
lin (Ig)E reactions to antigen 5 is well docu-
mented (Huang et al. 1991; van Neerven et
al. 1996). However, SRW pollens contain 52
different antigens, suggesting that other HLA
II molecules can be involved in their recogni-
tion (Marsh et al. 1987; Stewart et al. 1996;
van Neerven et al. 1996). Furthermore,
knowledge of the sets of determinants pre-
sented by each HLA molecule is not known,
nor is the hierarchy of importance among
HLA class II molecules in ragweed allergen
presentation. In addition, specific HLA-DR
and DQ molecules have been implicated in
asthma (Gerbase-DeLima et al. 1997; Hizawa
et al. 1998; Malo and Chan-Yeung 2001;
Soriano et al. 1997). However, their role and
contribution in the development of allergic
asthma are difficult to assess in humans
because of their genetic heterogeneity. Do
particular HLA-DR or HLA-DQ alleles pref-
erentially present peptides that elicit Th2-
type cytokine production and promote
allergic asthmatic conditions? Are there Th1-
restricted determinants? Do some HLA class
II molecules protect against allergic reactions?
If so, how is protection from atopy main-
tained? To address these questions, it is neces-
sary to analyze systematically the variables of
the allergen, individual epitopes, and the pre-
senting HLA molecule to a population of T
cells. Such controlled in vivo studies are not
possible in the human system. HLA class II
transgenic (tg) mice provide an excellent
model for studying the genetic and molecular
basis of allergic response.
Production and
Characterization of HLA
Transgenic Mice
We have introduced HLA-DQ8 (HLA-
DQB1*0302, HLADQA1*0301) and 
HLA-DQ6 (HLA-DQB1*0601, HLA-
DQA1*0301) genes into H-2Aβ0 mice
(Bradley et al. 1997; Nabozny et al. 1996). H-
2Aβ0 mice have disrupted Aβ gene and there-
fore could not express H-2Aβ molecule.
Because these mice were of the H2b haplotype
and lacked the functional H2-E molecule, no
mouse class II moleculeswere expressed on the
cell surface. HLA tg mice express intact HLA
molecules on cells of the lymphoid system and
respond to several protein, peptide, and para-
sitic antigens (Abraham and David 2000;
Geluk et al. 1998; Krco et al. 2000; Kudva et
al. 2001; Pimtanothai et al. 2000; Raju et al.
2001). HLA-DQ molecules in H-2Aβ0 mice
are expressed on the lymph nodes, spleens,
thymus, lungs, and kidneys of transgenic mice
but not in liver, pancreas, or brain.
Approximately 25–40% of peripheral blood
lymphocytes express HLA-DQ molecules.
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Environmental factors play an important role in the rise and manifestation of allergic conditions
in genetically predisposed subjects. Increased exposure to indoor/outdoor allergens is a signiﬁcant
factor in the development of allergic sensitization and asthma. Recently, strong relationships
between the immune response to several highly purified allergens and specific human leukocyte
antigen (HLA)-DQ and -DR haplotypes have been reported. The major antigens from clinically
important allergens have been cloned and sequenced. However, whether innate structural features
of major allergens or peculiar immune recognition of these molecules contribute to the overly
robust immune responses is not known. We generated and used transgenic (tg) mice expressing
single HLA class II transgene(s) to characterize the allergen epitopes presented by particular HLA
class II molecules. Next, we generated in vivo models for asthma in the HLA tg mice by intranasal
challenge with allergenic extracts. Furthermore, we used a single epitope to induce an allergic lung
inflammation. Our system offers a sophisticated technique for systematically identifying the
genetic (individual human class II) and antigenic (individual allergenic epitopes) basis of asthma
sensitivity and has important implications for new treatment strategies. Keywords: antigens/pep-
tides/epitopes, asthma, HLA, in vivo animal model, MHC, short ragweed allergen,
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transgenic/knockout. Environ Health Perspect 111:245–250 (2003). [Online 21 January 2003]Using a panel of monoclonal antibodies spe-
cific for Aα (clone 7-16-17), Aβ (clone
25-5-16), and Eα/β (clone Y-17) subunits,
we detected no cell surface expression of
hybrid class II. Thus, the HLA-DQ8 and
HLA-DQ6 mice express intact human class II
molecules in the absence of endogenous
mouse or hybrid molecules.
Flow cytometry analysis of spleen mono-
nuclear cells obtained from HLA-DQ6 and 
-DQ8 mice revealed that DQ transgene is
expressed on 7.38–15.41% of CD3+ cells,
2.71–8.15% of Mac1α+ cells, 25.68–32.51%
of B220+ cells, and 0.9–1.53% of CD11c+
cells (Chapoval et al. 1999). In bronchoalveo-
lar lavage (BAL), 80.66–92.92% of Mac1α+
cells and 79.68–90.33% of B220+ cells coex-
pressed DQ antigen (Chapoval et al. 1999).
There was no signiﬁcant difference in trans-
gene expression between HLA-DQ6 and
HLA-DQ8 mice. Expression of the
HLA-DQ molecule in H-2Aβ0 mice induces
the selection of CD4+ Vβ TCR+ cells and
restores the CD4+ T-cell population in the
periphery to a substantial level (5.0–9.3%).
The specific staining of mouse lungs for
HLA-DQ expression was performed and sec-
tions were examined using light microscopy.
This study demonstrated that the expression
of HLA class II molecules in normal lung tis-
sue in tg mice is similar to that in humans
(Chapoval et al. 1999). In addition to the pro-
fessional APC in lungs, lung alveolar and
bronchial epithelial cells and vascular endothe-
lial cells expressed HLA-DQ molecules.
We have generated tg mice expressing
HLA-DR2 (DRB1*1 502), DR3
(DRB1*0301), and DR4 (DRB1*0401)
(Geluk et al. 1998; Pan et al. 1998, 1999).
The DR molecules are also expressed on the
cell surface, interact with CD4+ T cells, and
positively/negatively select various T-cell recep-
tor-bearing subsets and present antigens. The
DR4 mice can present type II collagen and
derived peptides and develop mild arthritis
(Pan et al. 1998, 1999). Thus, the DR mole-
cules in tg mice are biologically functional.
Identiﬁcation of HLA Class II
Restricted Epitopes of
Allergens in Transgenic Mice
Recent cloning and sequencing of cDNAs
that encode major allergens (Gregoire and
Chapman 2001; Ledford 1994; Stewart and
Thompson 1996) has allowed T-cell epitope
mapping in humans using long-term T-cell
clones and lines (Bohle et al, 2000; de Silva et
al. 2000; Dhillon et al. 1992; Katsuki et al.
1996). However, in vitro cloning procedure
could bias toward certain T-cell response (van
Neerven, 1996) rendering polyclonal T cells
as better representatives of epitope diversity.
Furthermore, although studies with T-cell
clones from atopic patients might suggest
potential epitopes, they do not provide a
comprehensive picture of important epitopes
for all class II molecules. Conventional mouse
models do not fully reﬂect immune response
to allergen seen in humans because major his-
tocompatibility complex (MHC) II molecules
are mouse derived. HLA II tg mice provide a
powerful model for an exhaustive characteri-
zation and identification of the antigenic
determinants on allergens.
In the past years, HLA tg mice have been
used to identify epitopes on several autoim-
mune disease-related antigens such as collagen
and cartilage glycoprotein, the autoantigens
associated with arthritis (Cope et al. 1999;
Krco et al. 1999), glutamic acid decarboxylase
and insulin associated with type 1 diabetes
(Abraham et al. 2000; Kudva et al. 2001; Raju
et al. 1997), nicotinic acetylcholine receptor
involved in myasthenia gravis (Raju et al.
2001), RO60 (SS-A) lupus-related antigen
(Paisansinsup et al. 2000), myelin basic
protein, myelin olygodendrocyte glycoprotein
and proteolipid protein implicated in the devel-
opment of multiple sclerosis (Das et al. 2000;
Ito et al. 1996; Madsen et al. 1999; Khare M,
David CS. Personal communication). In addi-
tion, the use of HLA II tg mice has proven to
be a valuable tool for identiﬁcation of T-cell
epitopes on malarial parasites (Pimtanothai et
al. 2000) and mycobacterial antigens (Geluk et
al. 1998) that could be used to generate a new
type of more effective subunit vaccines.
Moreover, recent studies of HLA II tg mouse
immune responses to tumor-associated proteins
allow us to identify epitopes of potential clinical
value for design of anticancer vaccines
(Chapoval et al. 2001a; Wilson K, David CS.
Personal communication).
We tested the ability of HLA-DQ tg
mice to respond to house dust mite (Krco et
al. 2000; Neeno et al. 1996), ragweed
(Chapoval et al. 1998), and cockroach
(Papouchado et al. 2000) allergens. The
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Figure 1. This diagram depicts schematically how the allergic response develops. Allergens are derived
from different sources such as cockroaches, ragweed pollens, and house dust mites that are currently
being investigated in our laboratory. Antigen-presenting cells (APC) capture, process, and present aller-
gen as an allergen-derived peptide fragment in the contest of specific MHC II (HLA II) molecules.
Recognition of this complex by T-cell receptor (TCR) on CD4+ T cells leads to a cytokine (IL-4) mediated
clonal expansion of the T helper 2 (Th2) type cells. Several factors bias the development of Th2 type of
response (Romagnani 2000). Allergen also interacts with B-cell receptor and is internalized by B cells fol-
lowing antigen (Ag) processing and presentation to the TCR on expanded population of Ag-specific Th2
cells. This together with costimulatory factors and cytokines leads to clonal expansion and differentiation
of the B cells involved. B cells switch to Ag-speciﬁc antibody (Ab) production, including IgE and IgG1 in
mice (IgE and IgG4 in humans, correspondingly). The allergen-speciﬁc Ab bind to their receptors displayed
on mast cells. Re-exposure to allergen and subsequent crosslinking of Ab molecules leads to mast cell
activation, degranulation, and release of mediators. Th2 cells generate IL-5, which increases the produc-
tion of eosinophils (Eos) in bone marrow, promotes their release into circulation, and regulates their
migration into the lung tissue. Activated eosinophils release their toxic granule contents [major basic pro-
tein (MBP), eosinophil cationic protein (ECP), eosinophil peroxidase (EPO)] and cause serious tissue dam-
age. Th2 cytokine can directly contribute to the tissue damage or airway remodeling in asthma (Elias et al.
1999) by inducing and promoting a mucus hypersecretion. They also act on ﬁbroblasts (Fb) and favor the
subepithelial ﬁbrosis. Asthma and allergy involve a variety of steps and pathways, all of which are inﬂu-
enced by genetics as well as environmental factors.response of HLA-DQ tg mice to the whole
SRW extract was examined. Mice were
immunized subcutaneously with SRW in
complete Freund adjuvant. Seven days later
draining lymph nodes were isolated and
mechanically dispersed into a single-cell sus-
pension. Lymph node cells (LNC) were incu-
bated in vitro with various concentrations of
SRW (Figure 2). Proliferation was assessed by
3[H] thymidine incorporation and expressed
as the change (∆) in counts per minute (cpm)
over the cell cultures without SRW.
Stimulation of LNC with SRW resulted in
strong T-cell proliferation in a dose-depen-
dent manner giving peak ∆ of 25,824 and
14,312 cpm for HLA-DQ6 and HLA-DQ8
mice, respectively. HLA-DQ6/DQ8/H-2Aβ0
mice were unresponsive to any dose of SRW
at any point in time. Interleukin (IL)-5 and
IL-10 were the primary cytokines produced by
in vitro challenged LNC of SRW-primed
transgenic mice, suggesting that Th2 response
was generated in both transgenics (Chapoval
et al. 1998). To identify the subpopulation of
T cells necessary for responses to SRW in
transgenic mice, monoclonal antibodies
(mAb) with different speciﬁcity were added to
the wells containing cultures of LNC with
SRW. Proliferation was signiﬁcantly inhibited
or completely eliminated in cultures with
either anti-CD4 or anti-DQ mAb. No signif-
icant effect was observed in cultures contain-
ing mAb specific for mouse CD8, H-2Ab,
H-2Aβb, H-2E/βb, or for human MHC class
I molecules. Thus, the in vitro response to
SRW extract in HLA-DQ6 and HLA-DQ8
transgenic mice is mediated by CD4+
HLA-DQ–restrictedT cells.
Overlapping peptides spanning the entire
amino acid sequence of antigen 5 from SRW
were used to identify immunodominant and
cryptic determinants in HLA-DQ6 and
HLA-DQ8 tg mice (Chapoval et al. 1998).
To identify immunodominant determinants,
mice were immunized with individual over-
lapping peptide and LNC were challenged in
vitro with relevant peptide. To identify cryp-
tic epitopes, mice were immunized with
crude allergenic SRW extract and LNC were
challenged in vitro with either SRW or indi-
vidual peptide representing antigen 5. SRW-
immunized HLA-DQ6 mice respond
to peptide 11-30 of Amb a 5, whereas
HLA-DQ8 mice strongly recognize peptide
1-20 (Table 1). We concluded that a natu-
rally processed epitope for HLA-DQ6 mole-
cule resides within residue 10-20 or residue
18-30, whereas for HLA-DQ8 molecule it is
residue 1-10 or 8-20. When immunized with
peptides, HLA-DQ6–restricted T-cell
responses were detected to two determinants
(residues 1-20 and 11-30) on Amb a 5. In
contrast, LNC of HLA-DQ8 mice recog-
nized three Amb a 5 determinants (residues
1-20, 11-30, and 21-40). Therefore, there is
at least one HLA-DQ6–restricted determi-
nant within the region 1-30 of antigen 5, and
there are at least two HLA-DQ8–restricted
determinants within residue 1-40. We are
performing truncation analysis to precisely
localize critical residues (Krco et al. 2000).
Control H-2Aβ0 mice failed to show a pro-
liferative response to any of the peptides. The
mAb inhibition studies demonstrated that
the immune response to individual allergen
peptide in tg mice depended on CD4+ T
cells and was HLA-DQ restricted (Chapoval
et al. 1998). With knowledge of T-cell epi-
topes on allergens, we are exploring new
strategies for immune intervention in allergic
diseases by specifically interfering with the
interaction among APC, allergen, and T
lymphocyte.
HLA Transgenic Mice as Model
for Allergen-Induced Asthma
The conventional murine models of antigen-
induced experimental asthma have been extra-
ordinarily helpful in addressing selected
pathogenetic issues (Krinzman et al. 1996;
Kung et al. 1994; Renz et al. 1992).
Generation and use of transgenic and knock-
out mice for the multitude of mouse cytokines
and their receptors (Borchers et al. 2001;
Cohn et al. 2001; McMillan et al. 2002; Wang
et al. 2001; Zhu et al. 2001), cells (Chapoval
et al. 2001b; Corry et al. 1998; MacLean et al.
1999; Zuany-Amorim et al. 1998), chemokine
receptors (Lukacs et al. 2001; Schuh et al.
2002), costimulatory (Gonzalo et al. 2001;
Jember et al. 2001; Mehlhop et al. 2000),
adhesion (Fiscus et al. 2001; Wolyniec et al.
1998), and signaling (Das et al. 2001) mole-
cules demonstrate new evidence for the role
and signiﬁcance of the immune system in the
mechanisms of allergic tissue inflammation
and airway hyperreactivity.
To study the role and contribution of
speciﬁc HLA class II molecules in the patho-
genetic mechanism in atopic diseases and
asthma, H-2Aβ0, HLA-DQ6, and
HLA-DQ8 mice were actively sensitized and
later challenged intranasally with SRW
(Chapoval et al. 1999, 2002). In a sensitiza-
tion phase, SRW was applied intraperi-
toneally on day 0 and day 7 with aluminum
hydroxide as an adjuvant. Seven days after the
sensitization phase, airway inﬂammation was
induced by application of dialyzed extract
into the respiratory tract two times at 6 hr
apart. Vehicle-sensitized control mice were
injected with an equal volume of aluminum
hydroxide suspension in phosphate-buffered
saline (PBS), and challenged intranasally with
PBS alone. The development of disease was
evaluated both histologically and physiologi-
cally at 48 hr after challenge. After immuniza-
tions and challenge, HLA-DQ6 and
HLA-DQ8 tg mice had an increase in cell
accumulation in the BAL (Figure 3) and
perivascular and peribronchial inﬂammatory
infiltrates in the lung tissue (Figure 4). The
severe inflammatory pulmonary reaction
involved predominantly eosinophils (Figures
3 and 4). The in vivo response to SRW was
mediated by HLA-DQ–restricted CD4+ T
cells (Chapoval et al. 1999). H-2Aβ0 mice
did not show any histopathologic features of
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Figure 2. T-cell response to short ragweed aller-
genic extract in (A) HLA-DQ6 and (B) HLA-DQ8 tg
mice. Seven days after in vivo priming with SRW,
puriﬁed LNC were challenged in vitro with increas-
ing doses of SRW. MHC II knockout mice were
unresponsive to any dose of SRW at any point in
time (data not shown).
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Table 1. HLA-DQ6 and HLA-DQ8 tg mice respond to peptides representing allergen 5 of short ragweed pollen.a
Mice immunized with SRW Mice immunized with peptide
HLA-DQ6 HLA-DQ8 HLA-DQ6 HLA-DQ8
1-20 1-20 1-20
11-30 11-30 11-30
21-40
aAmino acid sequence of allergen 5 (Chapoval et al. 1998):
11 0 2 03 0 4 0 4 5
LVPCAWAGNVCGEKRAYCCSDPGRYCPWQVVCYESSEICSKKCGK disease (Figures 3 and 4) and the T-cell
response to subsequent rechallenge with
SRW was absent in these mice. HLA-DQ6
mice were treated with anti-DQ mAb by
intraperitoneal injections 24 hr before, simul-
taneous with, and after each SRW applica-
tion. This treatment signiﬁcantly lowered the
number of BAL total cells, eosinophils, and
lymphocytes recovered from allergen-sensi-
tized HLA-DQ6 mice, suggesting an impor-
tant role for HLA molecules in the
development of allergic inﬂammation in our
model (Figure 3).
It has been ﬁrmly established that allergic
inﬂammatory responses depend on the pres-
ence of Th2 cells (Krug and Frew 1997). As
such, we examined BAL and spleen MNC
cultures for cytokine expression. SRW treat-
ment induced local lung IL-5 and IL-13
production in HLA-DQ mice with unde-
tectable levels of interferon-γ (Chapoval et
al. 1999, 2002) indicative for Th2 effector
function. Similar to our observations in
BAL, direct analysis of cytokine synthesis in
spleen MNC cultures of HLA-DQ6 mice
also demonstrated the production of Th2
cytokines (Chapoval et al. 2002). Thus, the
immune system of HLA-DQ tg mice exhibits
Th2 cell effector activity in local lymphoid
and target tissues. None of Th2 cytokines was
detected in BAL and culture supernatant
preparations obtained from H-2Aβ0 control
animals, suggesting that their inability to
receive CD4+ T-cell stimulation from MHC
II molecules leads to a complete failure to
express Th2 type cytokines and allergen-spe-
ciﬁc Ab (Chapoval et al. 1999) or to develop
allergic eosinophilic airway inﬂammation.
Human asthma is characterized and its
severity is diagnosed by heightened airway
reactivity to varying concentrations of nonspe-
ciﬁc bronchoconstrictors or spasmogens such
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Figure 3. Cytospin analysis of BAL cells from SRW-sensitized and -challenged HLA-DQ tg mice. BAL ﬂuids
were collected at 48 hr after intranasal challenge, total leukocyte numbers were determined with standard
hemocytometer, and differential cell counts were made using Giemsa-stained cytospin slides. Total BAL
cell numbers: H-2Aβ0, 674 x 103; HLA-DQ6, 1,460 x 103; HLA-DQ8, 1,048 x 103; HLA-DQ6, anti-DQ, 556 x 103,
correspondingly.
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Figure 4. Histopathology or lung tissue stained with (A,C) hematoxylin/eosin (light microscopy) or with
(B,D) anti-mouse eosinophil major basic protein mAb (confocal microscopy). (A,C) There was no inﬂamma-
tion in lung tissue of H-2Aβ0 mice; a severe inﬂammation was observed in HLA-DQ6 tg mice. (B,D) Speciﬁc
immunohistochemical staining for eosinophils revealed them as a majority of perivascular (B) and peri-
bronchial (D) inﬂammatory cell inﬁltrates in HLA-DQ tg mice. Abbreviations: AV, airway vessel (bronchi-
ole); BV, blood vessel.
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Figure 5. Respiratory system physiology of (A) PBS-
treated and (B) SRW-sensitized and -challenged tg
mice. Abbreviations: Te, expiration time; RT, relax-
ation time; Pef, peak expiratory flow; Pif, peak
inspiratory flow. Airway reactivity was measured
48 hr after the last intranasal challenge by record-
ing respiratory pressure curves by whole body
plethysmography (Buxco Electronics Inc., Sharon,
CT). After establishing a stable baseline of breath-
ing in the plethysmograph, we exposed mice for 3
min to nebulized PBS and subsequently increasing
concentrations of nebulized methacholine in PBS.
After each nebulization, recordings were taken for
3 min. Values of PenH (index of airway obstruction)
were calculated by BioSystem XA software with
the following equation: PenH = (Te/RT-1) x (Pef/Pif). 
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Methacholine (mg/mL)as methacholine. To demonstrate these ten-
dencies in our tg mice, we used a noninvasive
barometric plethysmography, which allowed
us to measure lung physiology in conscious,
unrestrained mice (Hamelmann et al. 1997).
When we challenged PBS-treated or SRW-
treated mice with increasing concentrations
of methacholine in a whole-body plethysmo-
graph (Figure 5), we did not find an airway
hyperreactivity in MHC II knockout mice.
Allergen challenge induced strong hyperreac-
tivity in HLA-DQ6 mice, but hyperreactivity
was lower for HLA-DQ8 mice. The presence
of speciﬁc HLA-DQ molecules was required
for the induction of heightened airway reac-
tivity in vivo. Overall, transgenic expression
of two different HLA-DQ molecules in
MHC II knockout mice produced different
effects on several parameters of experimental
allergen-induced asthma (levels of BAL
eosinophilia, pulmonary inﬂammation, AHR,
BAL cytokine, and protein concentrations).
Thus, HLA class II transgenic mice offer the
opportunity to investigate the role of distinct
HLA molecules in allergen sensitivity and
may be useful for devising new immune
based therapies for allergic asthma.
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